大动脉狭窄流体组与中枢回病因在接受TAVR患者中的相互作用

相关实验视频

Updated: Sep 9, 2025

11:16

In vitro Assessment of Aortic Regurgitation Using Four-Dimensional Flow Magnetic Resonance Imaging

Published on: February 25, 2022

3.4K

Philipp M Doldi^1,2, Julius Steffen^1,2, Antonia Gehlich¹

¹Medizinische Klinik und Poliklinik I, LMU Klinikum, Munich, Germany.

European heart journal. Cardiovascular Imaging

|August 29, 2025

概括

在跨导管大动脉置换 (TAVR) 后,在不同大动脉狭窄 (AS) 流量组中产生显著影响的结果. 了解这些差异对于优化TAVR患者管理至关重要.

科学领域:

心血管医学
干预心脏病学
心脏外科

背景情况:

在不同流量组 (高梯度,古典低流量低梯度,悖论性低流量低梯度) 的大动脉静脉置换 (TAVR) 治疗策略仍在讨论中.
众所周知,同时发生的腹 (MR) 会使这些患者的结果恶化,但MR病因对不同AS亚型的具体影响尚不清楚.

研究的目的:

通过导管对大动脉置换 (TAVR) 后对患者结局的影响.
分析不同主动脉狭窄 (AS) 流量组的这些影响:高梯度 (HG-AS),经典低流量低梯度 (cLFLG-AS) 和悖论性低流量低梯度 (pLFLG-AS).

主要方法:

在2013年至2021年期间接受TAVR的2658名患者的回顾性分析.
根据病因分类:心房功能性 (aFMR),心室功能性 (vFMR) 或初级性MR.
评估的关键结果包括3年死亡率,TAVR后的MR改善和症状益处.

主要成果:

在2658名TAVR患者中,531名 (20. 0%) 患有中度或重度MR (MR ≥2+).
在cLFLG-AS组中,MR≥2+的患病率最高 (34. 2%). 在AS亚型中,MR病因有显著差异.
在MR≥2+患者中,三年死亡率较高 (HR1. 62). 这种关联在HG-AS和pLFLG-AS中是显著的,而不是cLFLG-AS. 在TAVR后的MR改善与HG-AS和cLFLG-AS的较低死亡率有关,但与pLFLG-AS无关.

结论:

转导管主动脉置换 (TAVR) 后的结局的关键决定因素是腹反 (MR) 的病因和严重程度.
根据特定的大动脉狭窄 (AS) 流量组,MR对TAVR结果的影响有很大差异.
这些发现强调需要根据TAVR候选物种的AS亚型和MR特征制定量身定制的管理策略.

相关概念视频

01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...

01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...

01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...

01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...

01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...